(Total Views: 581)
Posted On: 09/24/2020 9:31:32 PM
Post# of 145248
![](/m/assets/46931549/no_avatar_available_thumb.jpg)
as of the date of this filing $30 million has already been paid.by cydy
The Company estimates that initial ramp-up costs to manufacture commercial grade leronlimab at scale could total approximately $116 million, with approximately $69 million payable over the course of calendar 2020, of which $30 million has been paid as of the date of this filing, and approximately $23 million payable during calendar 2021, and approximately $24 million payable in January of 2022.
The Company estimates that initial ramp-up costs to manufacture commercial grade leronlimab at scale could total approximately $116 million, with approximately $69 million payable over the course of calendar 2020, of which $30 million has been paid as of the date of this filing, and approximately $23 million payable during calendar 2021, and approximately $24 million payable in January of 2022.
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)